



ASX Announcement

BOARD COMPOSITION CHANGES

MEDLAB CLINICAL LTD
A.C.N. 169 149 071
("Medlab" or "THE COMPANY")

Sydney, December 4, 2024 – Medlab Clinical Ltd (ASX:MDC) ("Medlab" or "the Company") is releasing the following update to stakeholders.

With a view to maximising value from a future transaction, changes have been made to the composition of Medlab's Board which reinforces its strategic credential in dealing with a transaction of this nature.

The process may involve engagement with current and new investors, as well as interested parties to achieve the ongoing success of the Company.

Resignation

Medlab advises that **Mr Matt Hudson** has recently resigned from the Company's board.

Medlab expresses gratitude to Matt for his time and diligent efforts in managing the Company on a care-taker mode, since Company entered trading suspension.

Appointment

Medlab is pleased to announce the appointment of **Mr Joshua Light** to the Company's Board as Non-Executive Directors.

Josh is a corporate finance specialist with broad expertise in investment banking and corporate advisory, particularly within the mining and resources sector. He has successfully managed and facilitated numerous M&A transactions and capital raisings across primary and secondary markets in Australia and North America.

Josh brings a deep understanding of base and critical metals and has coordinated various resource-focused acquisitions at the junior market level. His extensive understanding of listing rules and compliance ensures seamless transactional execution and robust regulatory support.

Josh holds a Bachelor of Science from Edith Cowan University.

As per ASX listing rule 3.16, the Company was required to immediately notify the market. The Company will ensure future adherence to this listing rule is prioritised.

-ENDS-

Announcement authorised by Medlab Clinical Ltd Board of Directors